Statins are a class of prescription drugs that lower blood cholesterol by blocking HMG-CoA reductase, the liver enzyme that controls how much cholesterol the body makes for itself. They are the most widely prescribed lipid-lowering medicines and the best-tested drugs in cardiovascular prevention. The point of taking one is not the number on a lab report but the event it predicts: a heart attack or a stroke. The partner entry Statins covers who is offered them, how doses are graded and what the side effects really look like.
What it measures
A statin is a treatment, not a marker, so there is no value to read off it. What gets measured is its effect: a standard lipid panel before treatment, then again a few weeks to a few months after starting or changing a dose.
The mechanism is simple. By blocking HMG-CoA reductase, a statin leaves liver cells short of cholesterol. They respond by putting more LDL receptors on their surface, pulling LDL (LDL, “bad” cholesterol) particles out of the blood. Triglycerides fall somewhat too, HDL rises slightly, and markers of inflammation such as hs-CRP tend to come down. The class includes atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin and pitavastatin, which differ in potency, duration and metabolism.
Typical values
Statins are graded not by milligrams but by intensity, the average LDL reduction a regimen produces:
| Intensity | Average LDL lowering | Common daily regimens |
|---|---|---|
| High | About half or more | Atorvastatin 40-80 mg; rosuvastatin 20-40 mg |
| Moderate | Roughly a third to a half | Atorvastatin 10-20 mg; rosuvastatin 5-10 mg; simvastatin 20-40 mg; pravastatin 40-80 mg; pitavastatin 1-4 mg |
| Low | Under about a third | Simvastatin 10 mg; pravastatin 10-20 mg; lovastatin 20 mg; fluvastatin 20-40 mg |
These are population averages, not promises. Individual response varies widely, and the choice of drug, dose and target belongs to the clinician who knows your other prescriptions and your kidney and liver function.
Why it matters for longevity
Pooled analyses of the randomized statin trials show that lowering LDL cholesterol reduces major vascular events, and that the size of the reduction tracks the size of the LDL drop rather than the particular drug used. In people who already have atherosclerotic disease, or are at clearly elevated risk, treatment also lowered all-cause mortality.
The relative benefit is fairly constant; the absolute benefit is not. The same proportional risk reduction means a great deal for someone after a heart attack and much less for a low-risk 45-year-old, which is why prescribing follows overall risk rather than a cholesterol number in isolation. Statins do not slow aging. They remove part of one of the leading causes of death, which is enough to shift life expectancy in treated high-risk groups.
What changes it
Whether a statin is offered at all usually turns on estimated risk, such as the ASCVD — 10-year risk of atherosclerotic cardiovascular disease, together with existing heart disease, diabetes, very high LDL or familial hypercholesterolemia. Diet, exercise, weight and smoking all move LDL and remain the foundation, but at high risk they rarely substitute for the drug, and inherited high cholesterol does not respond to lifestyle alone.
Once treatment starts, adherence is the biggest determinant of real-world benefit. Grapefruit juice, some antifungals, some antibiotics and several other drugs raise blood levels of certain statins, so a full medication list matters. Muscle aches are the most reported complaint; in blinded trials, including n-of-1 designs where people took statin and placebo in turn without knowing which, most of those symptoms appeared on placebo too, so stopping and restarting under supervision tells you more than quitting for good. Serious muscle damage is rare. Statin treatment slightly increases new diagnoses of type 2 diabetes, mostly in people already close to the threshold, and clinically important liver injury is uncommon. Where a statin is not enough or not tolerated, ezetimibe, bempedoic acid and PCSK9 inhibitors lower LDL by other routes. Do not start or stop one on your own.
Related reading
- Heart Health: A Prevention Guide for Longevity
- Coenzyme Q10 and Longevity: An Evidence Review
- Berberine, the Natural Metformin: An Evidence Review
Disclaimer. This article is for information only and does not replace medical advice. Talk to a qualified clinician before changing anything about your health.